Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: kenhott who wrote (31308)	5/26/2009 1:30:38 PM
From: rkrw	1 Recommendation Respond to of 52153

The difference is the Astellas bid was hostile so CVTX shopped around.

To: kenhott who wrote (31308)	5/26/2009 9:48:36 PM
From: Biomaven	Respond to of 52153

Somebody trying to stir things up maybe: Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of Cougar Biotechnology, Inc. BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of Cougar Biotechnology, Inc. (“Cougar Biotechnology” or the “Company”)(Nasdaq:CGRB - News) related to a proposal from Johnson & Johnson to acquire all of the outstanding shares of Cougar Biotechnology in an all-cash deal valued at approximately $1 billion. Under the terms of an agreement signed by the parties, Johnson & Johnson will initiate a tender offer, through a new wholly-owned subsidiary, to purchase all outstanding shares of Cougar Biotechnology at $43 per share. The investigation concerns possible breaches of fiduciary duty and other violations of state law related to the proposed acquisition.